Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CDXS 
Codexis Inc (CDXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CDXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.08
1 Year Target Price $7.08
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.65% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 247.71M USD | Price to earnings Ratio - | 1Y Target Price 7.08 |
Price to earnings Ratio - | 1Y Target Price 7.08 | ||
Volume (30-day avg) 7 | Beta 2.53 | 52 Weeks Range 1.90 - 6.08 | Updated Date 07/13/2025 |
52 Weeks Range 1.90 - 6.08 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -149.47% | Operating Margin (TTM) -271.59% |
Management Effectiveness
Return on Assets (TTM) -30.06% | Return on Equity (TTM) -115.53% |
Valuation
Trailing PE - | Forward PE 138.89 | Enterprise Value 247422098 | Price to Sales(TTM) 4.97 |
Enterprise Value 247422098 | Price to Sales(TTM) 4.97 | ||
Enterprise Value to Revenue 4.97 | Enterprise Value to EBITDA -10.67 | Shares Outstanding 82844800 | Shares Floating 60458514 |
Shares Outstanding 82844800 | Shares Floating 60458514 | ||
Percent Insiders 2.49 | Percent Institutions 83.85 |
Upturn AI SWOT
Codexis Inc
Company Overview
History and Background
Codexis Inc. was founded in 2002. It evolved from Maxygen, focusing on protein engineering for pharmaceutical and industrial applications. Key milestones include developing CodeEvolveru00ae technology and strategic partnerships with major companies.
Core Business Areas
- Codexis Enzymes: Development and sale of high-performance enzymes for pharmaceutical manufacturing, food, and other industries.
- CodeEvolveru00ae Platform: Licensing of the CodeEvolveru00ae protein engineering platform to partners for their internal enzyme development programs.
Leadership and Structure
The leadership team includes the CEO, CFO, and other executives. The organizational structure comprises R&D, manufacturing, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Enzymes for Pharmaceutical Manufacturing: Enzymes used in the synthesis of active pharmaceutical ingredients (APIs). Codexis faces competition from companies like BASF and DSM in the enzyme supply market. While exact market share is difficult to ascertain, Codexis is a significant player in specific enzyme applications. Revenue generated is not publicly broken down, and data on number of users is difficult to collect.
- Enzymes for Food Industry: Enzymes used in the manufacturing of food products such as human milk oligosaccharides (HMOs). Competitors include Novozymes and DuPont. While exact market share is difficult to ascertain, Codexis is a significant player in specific enzyme applications. Revenue generated is not publicly broken down, and data on number of users is difficult to collect.
Market Dynamics
Industry Overview
The enzyme market is driven by increasing demand for sustainable and efficient manufacturing processes. Growth is fueled by the pharmaceutical, food, and industrial sectors.
Positioning
Codexis is positioned as a leader in enzyme engineering, offering tailored solutions through its CodeEvolveru00ae platform. Its competitive advantages include its technology, expertise, and partnerships.
Total Addressable Market (TAM)
The global industrial enzymes market is estimated to reach billions of dollars. Codexis is well-positioned to capture a significant portion of the TAM through its innovative technology and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary CodeEvolveru00ae technology
- Strong partnerships with leading companies
- Expertise in enzyme engineering
- Customizable enzyme solutions
Weaknesses
- Reliance on partnerships for revenue
- Limited in-house manufacturing capacity
- Competition from larger enzyme suppliers
Opportunities
- Expanding into new enzyme applications
- Increasing demand for sustainable manufacturing
- Growth in the biopharmaceutical sector
- Development of novel enzyme products
Threats
- Competition from established enzyme suppliers
- Technological advancements by competitors
- Economic downturns affecting customer demand
- Regulatory changes
Competitors and Market Share
Key Competitors
- Novozymes (NVZMY)
- DSM (RDSMY)
- BASF (BASFY)
Competitive Landscape
Codexis has a competitive advantage in enzyme engineering but faces competition from larger, established enzyme suppliers.
Growth Trajectory and Initiatives
Historical Growth: Codexis has demonstrated revenue growth over the past several years, driven by partnerships and enzyme sales.
Future Projections: Analysts project continued revenue growth and improved profitability, driven by new enzyme applications and partnerships.
Recent Initiatives: Recent initiatives include expanding partnerships, developing new enzyme products, and investing in manufacturing capacity.
Summary
Codexis is a growing company with a strong technology platform and strategic partnerships. Its reliance on partnerships and competition are challenges. The enzyme market offers significant growth potential. Future performance depends on execution and innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and financial information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Codexis Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2010-04-22 | President, CEO & Chairman Dr. Stephen George Dilly MBBS, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 188 | Website https://www.codexis.com |
Full time employees 188 | Website https://www.codexis.com | ||
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.